Cargando…
Colonic Wall Thickening as the First Indicator of Relapse of Acute Lymphoblastic Leukemia
The gastrointestinal (GI) tract is a rarely reported site of extramedullary relapse of acute lymphoblastic leukemia (ALL). We report a patient being effectively treated with immunotherapy for relapsed ALL who was incidentally noted to have colonic wall thickening on imaging that was subsequently pat...
Autores principales: | Hathorn, Kelly E., Luskin, Marlise R., Caton, Michael Travis, DeAngelo, Daniel J., Saltzman, John R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791643/ https://www.ncbi.nlm.nih.gov/pubmed/31737733 http://dx.doi.org/10.14309/crj.0000000000000207 |
Ejemplares similares
-
Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
por: Shimony, Shai, et al.
Publicado: (2022) -
Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials
por: Hantel, Andrew, et al.
Publicado: (2021) -
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
por: DeAngelo, Daniel J., et al.
Publicado: (2020) -
Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
por: Chen, Joseph, et al.
Publicado: (2020) -
Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin
por: Kayser, Sabine, et al.
Publicado: (2022)